What is claimed is:

1. Use of a composition of latanoprost encapsulated in a liposome in the manufacture of a medicament for reducing a fat deposit in vivo, wherein the fat deposit is a subcutaneous fat deposit or a visceral fat deposit, the medicament is to be injected directly into the fat deposit, the liposome is formed solely of egg phosphatidylcholine or palmitoyloleoyl phosphatidylcholine, a concentration of latanoprost in the composition is 0.5 mg/mL to 3.0 mg/mL, and the composition reduces a number of adipocytes in the fat deposit by 5% to 90%.

2. The use of claim 1, wherein the number of adipocytes in the fat deposit is reduced by 10% to 90%.

3. The use of claim 2, wherein the number of adipocytes in the fat deposit is reduced by 35% to 90%.

4. The use of claim 1, wherein the concentration of latanoprost is 1.0 mg/mL to 2.3 mg/mL.

5. The use of claim 1, wherein a volume of 25 μL to 75 μl of the composition is injected for each 0.5 cm^3 to 1.0 cm^3 of the fat deposit.

6. Use of a composition of latanoprost encapsulated in a liposome in the manufacture of medicament for reducing a fat deposit in vivo, wherein the medicament is to be injected into an interstitial space adjacent to the fat deposit and the liposome is formed solely of egg phosphatidylcholine or palmitoyloleoyl phosphatidylcholine, the fat deposit is a subcutaneous fat deposit or a visceral fat deposit, and the effective amount of the composition reduces a number of adipocytes in the fat deposit by 5% to 90%.

7. The use of claim 6, wherein a concentration of latanoprost in the composition is 0.5 mg/mL to 3.0 mg/mL.

8. The use of claim 7, wherein the concentration of latanoprost is 1.0 mg/mL to 2.3 mg/mL.

9. The use of claim 6, wherein a volume of 25 µL to 75 µl of the composition is to be injected for each 0.5 cm^3 to 1.0 cm^3 of the fat deposit.

10. Use of a composition of latanoprost encapsulated in a liposome in the manufacture of a medicament for reducing a subcutaneous fat deposit in vivo, wherein the liposome is formed solely of egg phosphatidylcholine or palmitoyloleoyl phosphatidylcholine, a concentration of latanoprost in the composition is 0.5 mg/mL to 3.0 mg/mL, and the effective amount of the composition reduces a number of adipocytes in the subcutaneous fat deposit by 5% to 90%.

11. The use of claim 10, wherein the concentration of latanoprost is 1.0 mg/mL to 2.3 mg/mL.

12. The use of claim 10, wherein a volume of 25 µL to 75 µl of the composition is to be injected for each 0.5 cm^3 to 1.0 cm^3 of the fat deposit.

13. Use of an effective amount of a composition of latanoprost encapsulated in a liposome in the manufacture of a medicament in treating steatoblepharon in a subject, wherein the medicament is to be injected into a fat deposit in an eyelid of the subject an effective amount of a composition of latanoprost encapsulated in a liposome, wherein the liposome is formed solely of egg phosphatidylcholine or palmitoyloleoyl phosphatidylcholine, a concentration of latanoprost in the composition is 0.5 mg/mL to 3.0 mg/mL, and the effective amount of the composition reduces a number of adipocytes in the fat deposit by 5% to 90%.

14. The use of claim 13, wherein the number of adipocytes in the fat deposit is reduced by 10% to 90%.

15. The use of claim 14, wherein the number of adipocytes in the fat deposit is reduced by 35% to 90%.

16. The use of claim 13, wherein the concentration of latanoprost is 1.0 mg/mL to 2.3 mg/mL.

17. The use of claim 13, wherein a volume of 25 µL to 75 µl of the composition is to be injected for each 0.5 cm^3 to 1.0 cm^3 of the fat deposit.

18. Use of an effective amount of a composition of latanoprost encapsulated in a liposome in the manufacture of a medicament in treating proptosis in a subject, wherein the medicament is to be injected into an intraconal space of the subject an effective amount of a composition of latanoprost encapsulated in a liposome, wherein the liposome is formed solely of egg phosphatidylcholine or palmitoyloleoyl phosphatidylcholine, a concentration of latanoprost in the composition is 0.5 mg/mL to 3.0 mg/mL, and the effective amount of the composition reduces a number of adipocytes in the intraconal space by at least 35%.

19. The use of claim 18, wherein the proptosis is a result of thyroid-associated orbitopathy.

20. The use of claim 19, wherein the concentration of latanoprost is 1.0 mg/mL to 2.3 mg/mL.

21. The use of claim 18, wherein the subject suffers from Grave's disease or Hashimoto's thyroiditis.

22. The use of claim 21, wherein the concentration of latanoprost is 1.0 mg/mL to 2.3 mg/mL.

23. Use of an effective amount of a composition of latanoprost encapsulated in a liposome in the manufacture of a medicament for treating obstructive sleep apnea associated with an excess upper airway fat in a subject, wherein said medicament is to be injected into an upper airway fat deposit of the subject an effective amount of a composition of latanoprost encapsulated in a liposome, wherein the liposome is formed solely of egg phosphatidylcholine or palmitoyloleoyl phosphatidylcholine, a concentration of latanoprost in the composition is 0.5 mg/mL to 3.0 mg/mL, the effective amount of the composition reduces a number of adipocytes in the upper airway fat deposit by 5% to 90%.

24. The use of claim 23, wherein the upper airway fat deposit is located in the palate, the tongue, or the pharynx.

25. The use of claim 23, wherein the concentration of latanoprost is 1.0 mg/mL to 2.3 mg/mL.

26. The use of claim 23, wherein the number of adipocytes in the fat deposit is reduced by 10% to 90%.

27. The use of claim 26, wherein the number of adipocytes in the fat deposit is reduced by 35% to 90%.